Scott Armstrong

Scott Armstrong has been a driving force in the development of menin-MLL interaction inhibitors for leukemia, contributing to the understanding that the menin-MLL protein-protein interaction is essential for maintaining the leukemic transcription program in both MLL-rearranged and NPM1-mutant acute myeloid leukemia. His research demonstrated that menin inhibition causes rapid downregulation of HOXA genes and MEIS1, leading to leukemia cell differentiation and apoptosis. He contributed to preclinical studies supporting revumenib (SNDX-5613), which achieved accelerated FDA approval for relapsed/refractory KMT2A-rearranged acute leukemia. His work represents a paradigm success for targeting epigenetic protein-protein interactions in cancer.